78 related articles for article (PubMed ID: 22891675)
41. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.
Boffa MB; Koschinsky ML
Clin Biochem; 2007 Apr; 40(7):431-42. PubMed ID: 17331488
[TBL] [Abstract][Full Text] [Related]
42. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis.
Knecht W; Willemse J; Stenhamre H; Andersson M; Berntsson P; Furebring C; Harrysson A; Hager AC; Wissing BM; Hendriks D; Cronet P
FEBS J; 2006 Feb; 273(4):778-92. PubMed ID: 16441664
[TBL] [Abstract][Full Text] [Related]
43. Sulfamide as Zinc Binding Motif in Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa).
Halland N; Czech J; Czechtizky W; Evers A; Follmann M; Kohlmann M; Schreuder HA; Kallus C
J Med Chem; 2016 Oct; 59(20):9567-9573. PubMed ID: 27749053
[TBL] [Abstract][Full Text] [Related]
44. Association between genotype and plasma levels of thrombin-activated fibrinolysis inhibitor (TAFI) in the development of preeclampsia.
Acosta-Tejeda M; Baptista-González H; Rosenfeld-Mann F; Trueba-Gómez R; García-Latorre E
Thromb Res; 2011 Oct; 128(4):e39-42. PubMed ID: 21708401
[TBL] [Abstract][Full Text] [Related]
45. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis.
Mosnier LO; Meijers JC; Bouma BN
Thromb Haemost; 2001 Oct; 86(4):1040-6. PubMed ID: 11686322
[TBL] [Abstract][Full Text] [Related]
46. Coagulation-fibrinolysis changes during off-pump bypass: effect of two heparin doses.
Paparella D; Semeraro F; Scrascia G; Galeone A; Ammollo CT; Kounakis G; de Luca Tupputi Schinosa L; Semeraro N; Colucci M
Ann Thorac Surg; 2010 Feb; 89(2):421-7. PubMed ID: 20103314
[TBL] [Abstract][Full Text] [Related]
47. Phosphinanes and Azaphosphinanes as Potent and Selective Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa).
Schaffner AP; Sansilvestri-Morel P; Despaux N; Ruano E; Persigand T; Rupin A; Mennecier P; Vallez MO; Raimbaud E; Desos P; Gloanec P
J Med Chem; 2021 Apr; 64(7):3897-3910. PubMed ID: 33764059
[TBL] [Abstract][Full Text] [Related]
48. Selenium-containing small molecules.
Guo H
Commun Chem; 2022 Oct; 5(1):138. PubMed ID: 36697609
[TBL] [Abstract][Full Text] [Related]
49. Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.
Sillen M; Declerck PJ
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916027
[TBL] [Abstract][Full Text] [Related]
50. Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?
Claesen K; Mertens JC; Leenaerts D; Hendriks D
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477318
[TBL] [Abstract][Full Text] [Related]
51. Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
Bunnage ME; Blagg J; Steele J; Owen DR; Allerton C; McElroy AB; Miller D; Ringer T; Butcher K; Beaumont K; Evans K; Gray AJ; Holland SJ; Feeder N; Moore RS; Brown DG
J Med Chem; 2007 Nov; 50(24):6095-103. PubMed ID: 17990866
[TBL] [Abstract][Full Text] [Related]
52. TAFIa inhibitors in the treatment of thrombosis.
Bunnage ME; Owen DR
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):480-6. PubMed ID: 18600565
[TBL] [Abstract][Full Text] [Related]
53. Design and characterization of a selenium-containing inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa), a zinc-containing metalloprotease.
Yoshimoto N; Sasaki T; Sugimoto K; Ishii H; Yamamoto K
J Med Chem; 2012 Sep; 55(17):7696-705. PubMed ID: 22891675
[TBL] [Abstract][Full Text] [Related]
54. Structural basis for inhibition of carboxypeptidase B by selenium-containing inhibitor: selenium coordinates to zinc in enzyme.
Yoshimoto N; Itoh T; Inaba Y; Ishii H; Yamamoto K
J Med Chem; 2013 Oct; 56(19):7527-35. PubMed ID: 24010887
[TBL] [Abstract][Full Text] [Related]
55. Structural basis for the selective inhibition of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) by a selenium-containing inhibitor with chloro-aminopyridine as a basic group.
Itoh T; Yoshimoto N; Hirano Y; Yamamoto K
Bioorg Med Chem Lett; 2018 Jul; 28(13):2256-2260. PubMed ID: 29859906
[TBL] [Abstract][Full Text] [Related]
56. Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis.
Vercauteren E; Gils A; Declerck PJ
Semin Thromb Hemost; 2013 Jun; 39(4):365-72. PubMed ID: 23457049
[TBL] [Abstract][Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
